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Summary 
Background 
The long-term progression of coronary artery disease (CAD) as defined by the 
natural course of the disease years after a myocardial infarction (MI) is an important 
area of clinical research that has been poorly studied. The “long-Term rIsk, clinical 
manaGement and healthcare Resource utilization of stable coronary artery dISease 
in post myocardial infarction patients” (TIGRIS) study was designed to address this 
knowledge gap by evaluating patient management and clinical outcomes following MI 
in different regions worldwide. 
Methods 
TIGRIS (ClinicalTrials.gov Identifier: NCT01866904) is a multi-center, observational, 
prospective, longitudinal study enrolling patients with history of MI 1 to 3 years 
previously and high-risk of developing atherothrombotic events in a general practice 
setting. Overall, 9,225 patients are being followed in 369 different centers worldwide, 
which will allow for the description of regional differences in patient characteristics, 
risk profiles, medical treatment patterns, clinical outcomes, and healthcare resource 
utilization. Patients will be followed for up to 3 years (minimum of 2 years).  
Discussion 
We report the rationale, design, patient distribution and selected baseline 
characteristics of the TIGRIS study. This study will describe real-world management, 
quality of life, and healthcare resource utilization for patients with stable CAD at least 
1-year post MI. 
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1. Introduction 
Atherosclerotic plaque ulceration, erosion, or rupture, followed by platelet activation 
and thrombus formation is thought to constitute the main cause of cardiovascular 
(CV) events. Medical management of patients after an acute coronary syndrome 
(ACS) is based on multiple randomized clinical trials defining the acute, typically first 
year, treatment after the index event. While evidence-based management has 
reduced mortality significantly in recent years, patients surviving the first year after an 
ACS remain at high-risk for future CV events.1-4 This risk is aggravated by distinct 
comorbidities, including hypertension, diabetes mellitus and chronic renal dysfunction 
as well as a history of recurrent myocardial infarction (MI) or documented history of 
angiographic evidence of multi-v ssel coronary artery disease (CAD).5-7 These 
comorbidities will also impact on medical management. 
 With better survival of the first year after an ACS, the prevalence of this 
high-risk population is growing worldwide, and rehospitalization remains frequent and 
unchanged over decades.8, 9 Therefore, it is important to establish an understanding 
of the demographics, treatments, and outcomes of these patients over time. The 
availability of the “long-Term rIsk, clinical manaGement and healthcare Resource 
utilization of stable coronary artery dISease patients in post myocardial infarction 
patients” (TIGRIS) registry will complement the current armament of generally 
country-specific registries of variable design, that render extrapolation of 
observations to other countries and regions difficult.10, 11 Furthermore, the limited 
information that is available suggests that management patterns and outcomes may 
vary for different nations. Direct comparisons of regional differences in post-MI 
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management and outcomes would be facilitated through the standardized 
aggregation of this information across different countries. 
 The TIGRIS study was initiated to achieve this objective. The goal of TIGRIS is 
to provide a standardized prospective and longitudinal description of patient 
characteristics, events (per person years at 12 and 24 months), healthcare resource 
utilization and current treatment patterns as seen in a relatively unselected patient 
population post ACS. In this prospective observational study, patients from 25 
different countries with a previous MI 1 to 3 years before enrollment in the registry 
and at high-risk of developing future atherothrombotic events, will be followed for up 
to 3 years (minimum of 2 years). 
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2. Methods 
2.1 Overall study design 
TIGRIS (clinicaltrials.gov NCT01866904) is ongoing with a follow-up period of up to 3 
years. All patients undergo routine clinical assessments and receive the standard 
medical care, as determined by the treating physician. Patients will not receive any 
experimental intervention or treatment because of their participation in the study. The 
overall study design and patient flow chart is shown in Figure 1. 
2.2 Study population  
TIGRIS includes patients aged 50 years or older with a documented history of 
presumed spontaneous MI with their most recent MI having occurred 1 to 3 years 
prior to enrollment, and with at least 1 of the following risk factors: ≥65 years, 
diabetes treated with medication, documented history of a second MI >1 year prior to 
enrollment, multi-vessel CAD, and/or chronic non-end stage renal dysfunction 
(creatinine clearance calculated by Cockcroft Gault equation 15 mL/min to <60 
mL/min). All patients provided written informed consent for participation. The 
inclusion and exclusion criteria are described in Table 1.  
2.3 Aim and objectives 
The TIGRIS study will evaluate prospectively over a follow-up period of up to 3 years 
(minimum of 2 years), the risk for recurrent CV events in this high-risk stable post MI 
population. The primary objective is to evaluate clinical events and healthcare 
resource utilization associated with hospitalization for these events (duration of 
hospitalizations, and procedures) over the follow-up period. Secondary objectives are 
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to describe the rate of individual ischemic events as described above, including CV-
related death and death for unknown reasons and ischemic stroke, and to evaluate 
the incidence of bleeding events requiring medical attention. Other objectives are to 
describe associations between patient characteristics with quality of life and with the 
use (duration, adherence, discontinuation) of evidence-based therapies, association 
between oral antiplatelet therapy and clinical events (ischemic, death for any cause, 
and bleeding; including in high-risk subgroups such as the elderly, diabetic, renally 
impaired, or with recurrent MI), and to describe risk factor control in this high-risk 
population. 
2.4 Site selection and patient enrollment 
In total, 334 sites (333 active with at least 1 patient recruited, and 1 site with no 
patients) have participated in the TIGRIS study in 25 countries worldwide. A National 
Principal Investigator (NPI) was identified for each participating country. In an attempt 
to obtain a representative sample at a country level, recruitment of sites and subjects 
was initially based on predefined selection of physicians (office-based primary care 
physicians and cardiologists as well as cardiologists based in hospitals with 
outpatient clinics) by NPIs; this was intended to provide a distribution of physicians 
across regions and locations (ie, urban, suburban, or rural areas). The aim was for 
each participating site to enroll at least 10 patients. A complete list of participating 
sites and principal investigators is provided in Appendix I (supplementary materials). 
All patients will be followed up to 3 years in accordance with the overall patient flow 
chart shown in Figure 1.  
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2.5 Study duration and phases 
The planned duration of the study is from June 2013 (first patient in) until September 
2017 (last subject last visit). Data collection is performed during the initial visit, and 
every 6 months such that every patient will have between 2 and 3 years of follow-up. 
These follow-ups are conducted either by a telephone call or personal visit (Figure 1). 
This provides information on these high-risk patients for a period from a minimum of 
1 year to a maximum of 6 years since the index MI event. 
2.6 Study variables 
Variables obtained during the baseline visit were patient demographics including 
gender, age, race, place and type of residence, education level, and professional 
status. Sociodemographics including living arrangement status, income, and health 
insurance status were also collected. In addition, the prevalence of CV and bleeding 
risk factors, history of CAD and other CV disease as well as details of the medical 
history related to the index MI with a focus on antithrombotic medications has been 
assessed.  
 Variables from routine physical examination (heart rate, blood pressure [BP], 
weight, height, waist circumference) and from existing routine lab test (renal function 
tests, lipid profile, hemoglobin and glucose/glycated hemoglobin) if they were 
available and were performed within 3 months prior to the visit and up to 1 month 
after the visit (assuming no clinical events within this time window) were also 
captured in the initial visit. 
 Emphasis was paid to healthcare utilization related to CV or bleeding 
conditions during 6 months preceding enrollment.  
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 Measures of health status as assessed by the EuroQol 5-Dimensions (EQ-5D) 
and EuroQol Visual Analog Scale (EQ-VAS) were collected at baseline. This 
measures self-reported health status in 5 dimensions (EQ-5D™; mobility, self-care, 
usual activities, pain or discomfort, anxiety or depression) with 3 levels of severity 
(none, moderate, severe). For each patient, a single health state value, or utility, was 
calculated (EQ-Index and EQ-VAS scores) and set on a scale ranging from 0 (which 
corresponds to death) to 1 (EQ-Index) or from 0 to 100 (EQ-VAS; which corresponds 
to a best imaginable state of health).  
 Information was also collected at baseline regarding clinics/outpatient center 
characteristics. 
 During the follow-up period, clinical outcomes (death, CV events, and bleeding 
events), antithrombotic medications and other evidence-based medications, patient-
reported health status assessed by the EQ-5D are collected. Productivity loss such 
as sick leave for the patient and the caregiver which is event-related are being 
captured from a subset of around 10% of the study population from several countries 
where this information was considered particularly relevant (Nordic Region and The 
Netherlands). A complete list of variables captured in the study at baseline and 
during follow-up, are provided in Appendix II (supplementary materials).  
2.7 Collection of data 
The data are collected using electronic case report forms (eCRFs). Initial data 
collection was performed by the investigator. During the follow-up period, patients are 
either contacted via telephone every 6 months or attend for a study visit from the site. 
Follow-up phone calls are performed by either trained staff from the enrolling hospital 
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or from a designated call center, in accordance with a standard protocol to assist in 
recording of treatments, events and medical visits.  
 At each follow-up time point predefined clinical outcome events in the study as 
well as the variables related to associated healthcare utilization during hospitalization 
are collected directly from the treating physician/hospital through a standardized 
event confirmation eCRF and hospital module in the eCRF respectively in 
accordance with the following protocol. If, during interview, the patient or relative 
reports a predefined CV or bleeding-related hospitalization, the treating physician or 
hospital is contacted for confirmation of this event. Further information allowing 
determination of final diagnosis, primary cause of hospitalization, duration of hospital 
stay, procedures and interventions, and related healthcare resource utilization during 
hospital stay is collected from the treating physician or hospital directly through a 
standardized hospital module in the eCRF. If a death occurred, efforts are made to 
identify the cause of death (CV-related or non-CV) through the death certificate 
where available, or relatives, physicians, hospitals where it is not. 
2.8 Statistical methods and sample size determination 
This is a descriptive observational study without predefined hypothesis testing. The 
primary objective is to describe the incidence of CV events (time to first occurrence of 
any event from the composite CV endpoint of MI, unstable angina with urgent 
revascularization, stroke or death from any cause). The envisaged statistical methods 
included the description of the patients in accordance with their inclusion risk factors 
that define high-risk CAD: ≥65 years; treated diabetes; documented history of a 
second MI >1 year prior to enrollment; multi-vessel CAD; and/or chronic renal 
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dysfunction. Medication, and specifically the use of antithrombotic medication, over 
the study period will be described in terms of use at specific time points during follow-
up, as well as the duration of antithrombotic medication and changes in regimen. EQ-
5D data collected during the study will be reported descriptively. Healthcare resource 
utilization associated with events reported during the follow-up period will be 
assessed.  
 Events will be calculated both as risk (cumulative incidence) and rate using 
person-time methods whereby follow-up either terminates at the first occurrence or is 
censored at the last contact with the patient.  
 No formal power calculation has been undertaken for this descriptive study. 
Sample size was primarily driven by the country’s needs based on payer 
requirements from their markets. Initially a sample size of 10,170 patients was 
estimated; due to delays in ethical approval in some countries, 9,225 patients were 
ultimately recruited into the study.  
2.9 Ethics approval 
The final protocol was approved by the relevant ethics committee from each country, 
and the site ethics committee. The study is being performed in accordance with 
ethical principles consistent with the Declaration of Helsinki revision, International 
Conference on Harmonization Good Clinical Practice guideline, and the applicable 
legislation on non-interventional studies.  
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2.10 Funding and responsibilities 
TIGRIS is sponsored by AstraZeneca and is non-interventional in nature, with no 
drugs being supplied or funded. The TIGRIS Executive Committee comprises 12 
members (7 cardiologists, 1 clinical pharmacologist, 1 health economist and 1 
statistician, and 2 representatives from AstraZeneca). The executive committee with 
support from AstraZeneca is responsible for the design and conduct of this study, 
and all study analyses.  
2.11 Participating regions  
The participating regions were: Asia-Pacific, with 5 countries: Australia, China, India, 
Japan, and South Korea (n = 2,850 patients, 31%); Europe with 13 countries: 
Belgium, Denmark, Finland, France, Germany, Italy, Netherlands, Norway, Portugal, 
Romania, Spain, Turkey, and the UK (n = 4,240 patients, 46%); North America: 
Canada and USA (n = 1,024 patients, 11%); and South America, with 5 countries: 
Argentina, Brazil, Colombia, Mexico, and Venezuela (n = 1,111 patients, 12%) (Table 
2 and Figure 2).  
2.12 Patient characteristics 
Characteristics of patients in TIGRIS are shown in Table 2. Patients in Asia-Pacific 
and South America were younger, hence the risk factor age over 65 years was less 
frequently met as an inclusion criterion; there was a higher percentage of patients 
with treated diabetes mellitus in these 2 regions compared to patients from Europe or 
North America. On the other hand, the percentage of patients with a second prior MI 
(before the index MI) was higher in Europe and North America, while multi-vessel 
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CAD was seen more frequently in patients from North America and Asia-Pacific. The 
rates of chronic renal dysfunction were similarly distributed worldwide.  
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3. Discussion 
This report describes the rationale and design of the TIGRIS study, which is unique in 
being a study of unselected patients that reflects the heterogeneity of patients who 
have stable CAD but are at high-risk. Specifically, TIGRIS will address regional 
differences in patient characteristics, clinical outcomes, medical treatment patterns, 
and healthcare resource utilization of patients with high-risk of future CV events 1 to 
3 years post MI. 
 The risk of future CV events in patients with a history of MI is increased by 
comorbidities like diabetes mellitus, chronic kidney disease as well as the age and 
the complexity of CAD. While many randomized clinical trials have addressed this 
risk with emphasis on the first 12 months after an MI, little is known about the risk of 
subsequent ischemic events beyond this time in a “real-world” population. The 
improved survival post MI and the aging population are creating an emerging 
population for whom there is a problematic knowledge gap; specifically, there is a 
growing number of patients with a remote history of MI for whom there is little 
evidence to guide appropriate treatment. 
 Recently, Jernberg and colleagues published outcome data from a large 
Swedish national registry including 108,315 patients after MI with long-term follow-
up.12 Overall, 10% of the patients died during the hospital stay and within 1 week 
after hospital discharge, and an additional 12.3% over the following year. The 
cumulative rate of the CV composite outcome, including recurrent MI and stroke and 
CV death, was 18.3% in the first year after a MI. The CV risk remained high with 
9.0% in the next 12 months and 20.0% in the following 36 months. Similarly, 
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Rapsomaniki and colleagues investigated patients aged 65 years and older from 1 
year following a MI in the 4-nation APOLLO study. The adjusted risk of mortality over 
the subsequent 3 years ranged from 12.8% to 19.5%; the corresponding risks of 
hospitalized bleeding events ranged from 2.7% to 4.9%.13 These data, derived from 
datasets from France, Sweden, the United States and the United Kingdom, were 
generated for a variety of purposes using different collection and validation 
methodologies, hence it is difficult to ascertain whether the variation in event rates 
between countries reflected real differences, or variations in methodology. 
 In 2 recently reported acute dual antiplatelet therapy randomized clinical trials, 
mortality risk (Kaplan-Meier) in the 12 months following randomization were generally 
low eg, for PLATO (4.5% ticagrelor; 5.9% clopidogrel)14 and TRITON (3% prasugrel; 
3.2%; clopidogrel).15 PEGASUS investigated the long-term addition of ticagrelor to 
aspirin initiating treatment 1 to 3 years after a MI.16 The 3-year Kaplan-Meier 
mortality risk was 5.2% in the aspirin arm, substantially lower than that observed in 
the APOLLO program. Therefore, it is clear, compared to more selected and 
generally younger patients within randomized clinical trials, the unselected population 
has a substantially higher risk.17 This emphasizes the need for ‘real-world’ data 
collected using standardized rigorous consistent methodology to access outcomes 
during the years following a MI. 
 In addition to the provision of representative, general practice evidence, a 
major strength of TIGRIS is the focus on different countries. Notably, 30% of study 
patients derive from Asia-Pacific and 12% from South America, areas where the 
availability of such information is relatively limited. This study has already shown that 
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post-MI patients from Asia-Pacific and South America are younger and have a higher 
incidence of diabetes mellitus compared to patients from Europe or North America. 
Given these baseline differences in populations, TIGRIS will provide unique 
information on comparative outcomes and healthcare resource utilization in the years 
after a MI. Interpretation of these outcomes will be greatly aided though the recording 
of medical management patterns in different international settings and their 
association with clinical outcomes.  
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4. Conclusion 
In conclusion, TIGRIS is a unique study that documents demographics, 
comorbidities, treatment patterns and outcome data in unselected stable CAD 
patients with previous MI in general practice settings. Data are being collected 
internationally in a rigorous, standardized and consistent fashion providing a relevant 
picture of both the burden of recurrent events and variability in management and 
outcomes in this poorly studied patient population. 
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Figure legends 
Figure 1: Study design 
MI, myocardial infarction; QoL, quality of life 
Figure 2: Patient enrollment in “long-Term rIsk, clinical manaGement and healthcare 
Resource utilization of stable coronary artery dISease patients in post myocardial 
infarction patients” (TIGRIS) by country and region 
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Table 1: Inclusion and exclusion criteria 
Inclusion criteria Exclusion criteria 
• Age ≥ 65 years 
• Diabetes mellitus requiring medication  
• Documented history of a second prior 
presumed spontaneous MI (>1 year 
ago) 
• Documented history of angiographic 
evidence of multi-vessel coronary artery 
disease 
• Chronic, non-end stage renal 
dysfunction (15 mL/min ≤ creatinine 
clearance calculated by Cockcroft Gault 
equation <60 mL/min) 
 
• Presence of any condition or 
circumstance which in the opinion of the 
investigator could significantly limit the 
complete follow-up of the patient (eg, 
tourist, non-native speaker or does not 
understand the local language where 
interpreter services are not reliably 
available, psychiatric disturbances, 
alcohol or drug abuse) 
• Presence of serious/severe co-
morbidities in the opinion of the 
investigator which may limit life 
expectancy (<1 year) 
• Current participation in a blinded 
randomized clinical trial 
• Patients receiving treatment with 
ticagrelor beyond 12 months, or off label 
use of ticagrelor 
MI, myocardial infarction 
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Table 2: Patient characteristics 
  
Patients, n (%) 
All Asia-
Pacific & 
Australia 
Europe North 
America  
South 
America 
P 
Patients 9225 
(100) 
2850 
(30.9) 
4240 
(46.0) 
1024 
(11.1) 
1111 
(12.0) 
 
Inclusion risk factors 
Age ≥ 65 years 5766 
(62.5) 
1652 
(58.0) 
2814 
(66.4) 
666 
(65.0) 
634 
(57.1) 
<0.001 
Diabetes requiring medication 2805 
(30.4) 
999  
(35.1) 
1118 
(26.4) 
307  
(30.0) 
381 
(34.3) 
<0.001 
 Second prior MI 943 
(10.2) 
210  
(7.4) 
491 
(11.6) 
131 
 (12.8) 
111  
(10.0) 
<0.001 
 Multi-vessel CAD 6052 
(65.6) 
1921 
(67.4) 
2714 
(64.0) 
715  
(69.8) 
702  
(63.2) 
<0.001 
Chronic renal dysfunction 
(CrCl 15–60 mL/min) 
707 
(7.7) 
212  
(7.4) 
327 
(7.7) 
78  
(7.6) 
90  
(8.1) 
0.898 
CAD, coronary artery disease; CrCl, creatinine clearance; MI, myocardial infarction 
P-values estimated using Chi square test 
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Figure 1: Study design  
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Figure 2: Patient enrollment in “long-Term rIsk, clinical manaGement and healthcare Resource utilization of 
stable coronary artery dISease patients in post myocardial infarction patients” (TIGRIS) by country and 
region  
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APPENDIX I: TIGRIS National principal investigators (NPIs) and site study investigators 
 
Site name Investigator Sub-investigator(s) and coordinator(s) 
Asia 
China 
NPI: G Junbo 
Zhongda Hospital affiliated to Southeast University M Genshan Z Hong; Z Kongbo 
The 2nd Hospital affiliated to Guangzhou Medical 
University 
X Longgen C Luo 
Jinan Central Hospital affiliated to Shandong 
University 
S Guohai M Wei; W Fang; L Zhenhua 
Guangdong General Hospital C Jiyan F Yingqing; C Anping 
Zhongshan Hospital affiliated to Fu Dan University G Junbo Y Ming; X Lei 
Shanxi CDV hospital L Bao A Jian; S Jing 
Tianjin Union Medicine Center Y Zhuhua J Wang 
1st Hospital of Liao Ning Medical College T Guizhou M Liu 
Fuwai CV Hospital Q Shubin S Chunli; L Xiaoliang; Liu Rong; Z Jun; L Jia  
Beijing University 1st Hospital H Yong Z Bo  
The 1st Hospital affiliated to Chongqing Medical 
University 
L Han H Wei; C Jing 
Wuxi 2nd People’s Hospital J Yan   
The 1st Hospital of Jilin University Z Yang L Quan; W Yonggang 
1st Affiliated Hospital of Xi'an Jiaotong Univ, College W Yanni R Jie 
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Med 
The 1st Hospital affiliated to Lanzhou University Z Zheng Z Cunrui 
Tanjin Thoracic Hospital C Hongliang Z Yingyi 
Kunming General Hospital of Chengdu Military 
Region 
Y Lixia F Jun  
Wuxi People’s Hospital Y Zhenyu B Xiaoping; Y Fang; Z Xiaoxi 
The Affiliated Hospital of JiangSu University Y Jinchuan L Peijing; D Shu; W Jun 
India 
NPI: K Upendra 
Meenakshi Mission Hospital & Research Centre, 
Madurai 
R Sivakumar  J Balan  
Sir Ganga Ram Hospital JP Sawhney R Gehlot; MK Sharma 
Escorts Heart Institute, New Delhi U Kaul M Kent  
G. B. Pant Hospital V Mehta S Dalal 
Heart First Cardiac & Vascular Centre A Abhyankar A Mistry 
Fortis, Jaipur R Gupta B Mishra; S Chaturvedi; P Saxena; MK Sharma 
PRS Hospital, Trivandrum T Nair TC Aneesh 
West Fort Hitech Hospital PP Mohanan D Davies 
B. M. Birla Heart Research Center D Kahali S Chatterjee 
Fortis Hospital, Mohali HK Bali H Chauhan 
Fortis Hospital, Noida P Arora S Singh 
Ruby Hospital, Pune MS Hirematth R Pawar 
Madras Medical Mission A Mullasari R Bhavani 
Apollo Hospital PC Rath Adepu Aruna; Byomkesh Dikshit 
Japan 
NPI: S Yasuda 
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Iwate Medical University Y Morino T Ito; M Ishida; T Mifune; Y Ishikawa; S Nakajima; M Nagai; T 
Fusazaki; T Kimura; Y Shimoda; R Sakamto; Y Nakajima; K Komuro; 
Y Okuyama 
St Luke's International Hospital Y Nishi  
H Niinuma 
H Mitsuhashi; K Masuda; A Mizuno; T Asano; I Komatsu; M Kikuchi; 
S Kimijima 
Saiseikai Kumamoto Hospital K Nakao M Otaguro; K Nakano 
Kimitsu Chuo Hospital T Himi  M Yamamoto; H Fujimaki; Y Matsudo; T Sekine; K Hou; N Tonoike; S 
Tanaka; YHB Ge; S Tokimasa; A Fujino; S Hashidume 
Kumamoto University Hospital S Hokimoto H Ogawa; Kenichi Tsujita; H Soejima; E Yamamoto; S Tayama; T 
Tanaka; S Kojima; Y Arima; M Yamamuro; K Sakamoto; Y Izumiya; S 
Takashio; T Akasaka; Y Kimura; H Kurokawa; K Yamanaga; N 
Komuro; T Miyazaki; K Nishiyama; Y Kawanami 
Fujita Health University Y Ozaki E Watanbe; M Sarai; Y Kato; S Motoyama; H Naruse; Y Sobue; M 
Okumura; K Shiino; M Ohta; M Yamamoto; H Ito; Y Takakuwa; T 
Ichikawa; R Okuyama; M Ishikawa; M Koshikawa; Y Nagahara; M 
Miyagi; M Iwase; M Otsuki; N Hoshino; Y Hashimoto; T Muramatsu; 
S Matsui; S Ishikawa 
Sapporo Medical University Hospital T Miura A Hashimoto; T Miki; H Yoshida; N Kokubu 
Hirakata Kohsai Hospital  S Kitaguchi M Ozaki; R Yamauchi; Y Haruna; H Takenaka; K Takenaka; T 
Yamamoto; Y Kurozumi; N Takemoto 
Fukuoka University Hospital  K Saku A Kawamura; H Nishikawa; A Iwata; K Fujimi; E Yahiro; M Sugihara; 
A Ike; K Urabe 
Kitasato University Hospital J Ako T Tojo; T Shimohama; H Fukaya; T Naruke; H Shinagawa; J 
Kishihara; T Yanagisawa; Ouchi; K Yamamura 
Nippon Medical School Hospital W Shimizu K Asai; H Takano; G Takagi; K Kato; M Yoshikawa; K Murai; S 
Nakamura; Y Tsukada; T Yamamoto; K Akutsu; Y Hosokawa; K Inui; 
E Nakamura; K Kawakami 
Chikamori Hospital K Kawai R Imai; S Kubokawa; S Seki; S Yamamoto; Y Nakaoka; H Hosoda; T 
Matsui 
Chiba University Hospital Y Kobayashi K Sugimoto; Y Aoki; K Ishikawa; M Takahara; T Nakayama 
Fukui CardioVascular Center S Mizuno K Osato; I Moriuchi; T Murakami; K Misawa; H Kokado; M Saga; Ma 
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Tsuchida; Y Takasawa; J Yamaguchi; M Suzuki; N Maekawa; S 
Yoneda 
Ehime Prefectural Central Hospital  Y Kazatani H Okayama; T Yamada; G Hiasa; Y Kawada; M Kinoshita; T 
Shigematsu; H Nakagawa; T Ozaki; S Hosokawa; M Matsubara; K 
Fukuchi 
Ishikawa Prefecrual Central Hospital H Kanaya 
K Miwa 
T Matsubara: T Yasuda; M Inoue; Y Tamura; M Hashimoto; S Niwa; 
K Hakko 
Tohoku University Hospital H Shimokawa J Takahashi; Y Matsumoto; K Ito; K Hao; R Tsuburaya; E Ishida 
Yokohama City University Medical Center N Maejima K Kimura; T Ebina; K Hibi; K Konishi; N Iwahashi; T Matsuzawa; H 
Akiyama; Y Kimura; Y Minamimoto; K Matsushita; S Kataoka; S 
Ichikawa; S Kuji; K Takahashi; C Kawashima; K Hashiba; H 
Nakahashi; M Kosuge; M Ninomiya 
Osaka City University Hospital Y Minoru M Yoshiyama; S Ehara; T Hasegawa; K Shimada 
Gunma Prefectural Cardiovascular Center R Kawaguchi S Ooshima; H Kan;Y Miyaishi; M Maruhashi 
Seiyu Memorial Hospital Y Tomoguchi S Fujiwara; Y Ueno; M Gohda; K Takei; Y Shimomoto 
Shizuoka Hospital  T Onodera R Nawada; K Murata; R Takeuchi; Y Watanabe; T Yoshizaki; S 
Kageyama; N Hosoya; T Takagi; S Yamashita; G Matsukura; A 
Fujinami 
Tokushima Red Cross Hospital S Hosokawa Y Hiasa; R Ohtani; K Kishi; T Takahashi; K Yuba; H Miyajima; R 
Ogura; Y Tobbeto; T Yasuoka; Y Ooga; H Kiyobe; Y Shima 
National Cerebral and Cardiovascular Center M Ishihara; 
T Noguchi 
S Yasuda; M Fujino; M Nakanishi; T Arakawa; R Kumasaka; T 
Kanaya; S Honda; T Nagai; Y Goto; Y Asaumi; K Nakao; M 
Kawakami; R Yamada; A Matsuyama; Y Kawakami; T Nishimura 
Juntendo University Shizuoka Hospital S Suwa N Kubota; S Tsuboi; T Shimizu; H Wada; H Endo; Y Kato; M Sesoko; 
M Kunimoto; S Ouchi; J Shitara; K Shiba 
Oji General Hospital T Matsumoto J Ohata; D Yoshida; N Kato; H Hotta; T Ito; S Tanaka; H Narikawa 
Hyogo Prefectural Amagasaki General Medical 
Center  
T Miyamoto Y Takatsu; Y Sato; R Taniguchi; K Yoshitani; R Fukuhara; S Saga; T 
Kobayashi; H Shinomiya; S Imura; H Inazumi; T Kuragaichi; M Shiba; 
H Nakayama; C Uwajima; A Negimoto 
Tenri Yorozu Hospital S Enomoto; S Enomoto; K Kaitani; C Izumi; T Tamura; H Kondo; N Onishi; M 
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Y Nakagawa Miyake; Y Tamaki; K Takahashi; N Kuroda 
Kusatsu General Hospital  A Wada M Fujii; T Matsumoto; K Mori; A Taniguchi; S Kimura; Y Fujito 
Tokai University Hospital Y Ikari 
F Yoshimachi; N Ogata; N Shinozaki; N Masuda; G Nakazawa; T 
Murakami; T Nakano; M Sato; S Torii; H Nagamatsu; T Suzuki; H 
Shimizu; T Suzuki; S Minakawa; H Horinouchi 
Kurume University T Ueno  
S Yokoyama; T Nakayoshi; N Itaya; M Sasaki; H Chibana; Y Aoki; K 
Sasaki; Y Sugi; M Otsuka; E Ogura 
Hiroshima City Hospital K Nishioka Y Nakama; T Oka; K Dai; K Ooi 
South Korea 
NPI: Y-J Kim 
Wonju Christian Hospital J Yoon SH Han 
Pusan National University Hospital K Soo Cha HC Lee; J-H Oh; J-H Choi; HW Lee; J Lee; J Hong; SH Ji; WJ Kim  
Kosin University Gospel Hospital T-J Cha  IK Noh 
Chonbuk National University Hospital J-K Chae EJ Cho; JY Hong; SM Lee 
Keimyung University Dongsan Hospital C-W Nam M Y Shin; M H Choi 
Chung-Ang University Hospital S W Kim KH Kim; M Choi 
Inje University Haeundae Paik Hospital D Kim KN Park 
Chungbuk National University Hospital M-C Cho; SM 
Kim 
CS Lee; EK Kim  
Chonnam National University Hospital M-H Jeong KH Park; DS Sim; YJ Hong; A Choi; C Kim 
Gyeongsang National University Hospital Y-H Jeong; JS 
Koh 
CH Kwak; J-Y Hwang; JR Park; ES Kim  
Yeungnam University Hospital Y-J Kim D Shin; JS Park; SH Lee; U Kim; JW Son; KH Yim; YM Ha; HS Lee; 
JM Kim 
Chungnam National University Hospital S W Choi JH Lee; NM Jeon 
Australia 
NPI: D Brieger 
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Concord Hospital D Brieger K Xu  
John Hunter Hospital N Collins  A Gordon; E Hicks  
St George Hospital M Sader P Shrestha; K Dobinson; J Brimley; D Vrachas; E Watson 
Royal Brisbane and Women’s Hospital C Hammett L Carr; C Booth; S Hayman; A Brazzale; C Cosgrove; A Lin; G 
Goodman; L Palethorpe; L Hindom; L Lilwall 
Wollongong Hospital A Lee  P Hedge; D Devenney; T Fetahovic; S Mackay; J Gibbs  
Royal North Shore Hospital G Nelson M Ward; E Reid; A Loxten  
Princess Alexandra Hospital P Garrahy C Hall; C Sieg 
Sir Charles Gairdner Hospital P Thompson C-Di Camillo; H Anderson; L Ferguson; S Zafer; K Mohammadi; S 
Nagel 
Gold Coast Hospital R Jayasinghe L Howes; S Quinlan; T Brumbly 
Royal Melbourne Hospital D Eccleston  K Phan; J Ward  
Northern Hospital W van Gaal I Subiatko; N Rudd; M Park  
Fremantle Hospital A Whelan R Kamne; S Atique; T Nunn; A Rehmani; D Greenwell; G Tulloch; N 
Forrest 
Liverpool Hospital J French E Plotz; A Croucher 
Coffs Harbour Base Hospital J Waites V Joseph; P Keays; L Gill  
Epworth Hospital R Dick C Savage; B Slait  
Nambour General Hospital A Willson R Poulter; M Johnson; P Larsen; S Wadham; M Fellner; L Webber; K 
Greaves 
Europe 
Belgium 
NPI: M Vrolix 
ZOL Genk M Vrolix W Helsen; N Peters; C Swijsen 
OLV Aalst E Barbato; 
C Van Mieghem 
E Lievens; H Batjoens 
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AstraZeneca (AZ) St Augustinus Veurne M Detollenaere L De Bruyne; M Everaert 
AZ Klina F Cools N Simons; V Thyssen 
Imelda Bonheiden B Vankelecom Y Daelemans; C Vissers; R Janssens 
Maria Ziekenhuis Overpelt D Faes A Van Dorpe 
UZ Gent S Gevaert P Vervaet 
AZ Groeninge - Campus LS P Dejaegher M DeConinck 
Denmark 
NPI: H Nielsen 
Hjerteklinikken Plan 5 Regionshospitalet Randers H Rickers B W Friis; M Morsing 
Gentofte Hospital Hellerup                 J S Jensen J Laage-Petersen; LH Simonsen 
Rigshospitalet Hjertecentret, København L Holmvang A Karlsdottir; L Klovgaard; SB Nielsen; M Tarras-Wahberg 
Bispebjerg Hospital H Nielsen E Stokholm; B Hauggaard; D Petersen 
Ålborg Sygehus L H Rasmussen A Gammelmark; BG Sorensen; F Hellum; B Mortensen  
Amager Hospital, København S. J Brønnum-
Schou  
JB LLægelig; H Hempel; P Hadsund 
Haderslev Sygehus Kardiologisk sektion E V Friis C Markussen; I Christensen 
Finland 
NPI: I Tierala 
Turku University Hospital J Airaksinen  K Lahtonen; T Vasankari 
Tampere University Hospital S Vikman  V Rasanen; H Nappile; H Schemakka 
Keski-Suomen keskussairaala J Niva    
France 
NPI: T Cuisset 
Hôpital Pasteur E Ferrari L Marthoud; M Douillet 
Centre Hospitalier Louis Pasteur G Range C Laure 
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Centre Hospitalier de Versailles J L Georges J B Azowa 
CH St Joseph St Luc - LYON  O Dubreuil S Rio 
Hôpital de bligny A Ohanessian    
CHU de la Timone, Marseille T Cuisset  
Centre Hospitalier Sud Francilien, Service de 
cardiologie 
P Goube P Brito 
Germany 
NPI: S Blankenberg 
Klinikum Leverkusen gGmbH P Schwimmbeck I Wenzel 
Robert-Bosch-Krankenhaus T Schäufele I Wenzelburger  
Medizinische Klinik II am UKSH Campus Luebeck A Joost A Constantz; C Lüttecke; M Werner 
St. Josefs Hospital S Lüders U Venneklaas; I Medizin  
Univ.-Klinikum E Giannitsis H Deigentasch; S Stegmaier 
Klinikum Coburg gGmbH J Brachmann A Hoehn; U Göbel 
Klinikum Stadt Ludwigshafen Herzzentrum U Zeymer H Tolksdorf; S Baumann; N Veth-Leonhardt; P Riedmaier  
Kliniken Maria Hilf GmbH J vom Dahl U Gareis; B Krug-Hoeren 
Carl-von-Basedow-Klinikum Merseburg R Prondzinsky D Brosseit; S Koegel 
Elisabeth-Krankenhaus O Bruder  E Blank; V Reuter; M Steffen 
Universitäres Herzzentrum Hamburg D Westermann M Redlefsen; E P Tigges; M Hermes; I de Boer; M Redlefsen; M 
Karakas 
Universitätsmedizin der Johannes Gutenberg-
Universität Mainz 
T Gori I Walther; K Schulz 
Kardiologie am Tibarg F Stahl J Schiller 
University Heart Center Köln (Cologne) V Rudolph I Berg 
Sana Kliniken Lübeck J Weil M Miodek; T Köllner 
Heidekreis-Klinikum GmbH T Wittlinger  A-K Cohrs; V Wiechern 
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Vivantes Humboldt-Klinikum S Behrens M Gregor; R Sartipi 
CardioMed an der Alster B Subin N Zahn 
Charite, Campus Benjamin Franklin M Gross;  
SM Leistner 
S Kuehn 
Kardiologischen Gemeinschaftspraxis am Park 
Sanssouci Potsdam (St. Josefskrankenhaus) 
R Gaub V Gaertner 
Krankenhaus Dresden-Friedrichstadt II. Medizinische 
Klinik, Dresden 
S Schellong R Frommhold; B Voigts; L Pomper; J Gehre; M Hahn; M Langer; R 
Oelsner; T Wolf 
Cardiologicum Hamburg Praxis Wandsbek E Schmidt A Rexa; C Züge; V Bogoevska 
University of Ulm Medical Center S Markovic O Smirnova; A Maass; K Kraus; M Holl; U Schneeu 
Katholisches Krankenhaus St. Johann Nepomuk 
Medizinische Klinik II 
H Ebelt J Anacker 
Kardiologische Praxis J Bott M Erdas; J Bott 
Klinikum Frankfurt Höchst GmbH  C Kadel G Rahn; N Zulauf  
Medizinisches Beratungs- und Therapie-Zentrum 
Chemnitz GmbH 
K Kleinertz E von der Planitz; F Froehlich-Grimm; S Geserick 
Städtisches Klinikum München GmbH H Mudra P Setzer; J Fiedler; M Segerer; A Stote 
Vivantes Klinikum Neukölln H Darius A Maselli; G Biller; S Bodogh; S Gaulke 
Universitätsklinikum Erlangen S Achenbach C Uecker; S Fechner 
Synexus Frankfurt Research Centre, Frankfurt C Contzen N Freibott 
Synexus Berlin Research Centre, Berlin J Stößel F Bauch; T Trachte; AM Peukert 
Synexus Leipzig Research Centre K Kreutzmann; 
O Maus 
H Knopf; I Schiefer; N Zimmer; T Kusly 
Synexus Bochum Research Centre A Rinke A Rauscher; S Laube; P Doelken 
Bundeswehrzentralkrankenhaus Klinik für Innere 
Medizin 
C Bickel B Jürgens; M Halfter 
Italy 
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NPI: C Cavallini 
Ospedale Santa Maria della Misericordia C Cavallini E Grikstaite 
Presidio Ospedaliero Ca' Foncello, Treviso Z Olivari P Pantano 
Ospedale del Delta, Lagosanto GF Percoco;  
R Mazzucco 
  
Centro Cardiologico Monzino G Marenzi M De Metrio 
Ospedale Pediatrico Apuano G. Pasquinucci S Berti KJ Tyack; E Koni  
A.O.U. Federico II  PP Filardi T Losco; S Conte; L Casaretti 
Ospedale Misericordia e Dolce di Prato F Pestelli   
Azienda Ospedaliera Universitaria Policlinico Paolo 
Giaccone di Palermo 
S Novo C Vicari; C Paleologo 
Cardiologia del Policlinico S. Orsola di Bologna  A Branzi;  
C Rapezzi 
G Melandri; G Norscini 
Azienda Ospedaliera per l’Emergenza “Cannizzaro” A Fiscella;  
C Condorelli  
M Pardini 
Ospedale Unico della Versilia G Casolo M Pardini; L Robiglio; F Vivaldi 
ASL Sassari Ospedale Civile S.S. Annunziata P F Terrosu C Podddighe; C Denurra; G Sanna; A Canu; E Mura 
Azienda Ospedaliera di Rilievo Nazionale Antonio 
Cardarelli 
C Mauro D D'Andrea; A Sasso; F Furbatto 
The Netherlands 
NPI: AFM Kuijper 
BovenIJziekenhuis M van de 
Wetering 
L Klijn; SJ Groeneveld  
Rijnstate Ziekenhuis FF Willems E Maasen; J Marx; A Dekker; E Verhaah; P Verhoeven 
Tergooiziekenhuizen, loc. Blaricum G Hoedemaker M van der Zeijst  
IJsselland Ziekenhuis B J Berg van 
den 
I Hendriks 
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Reinier de Graaf Gasthuis E Ronner A Wissenburg; L van Setten van der Meer; L van der Hout; A 
Dijkshoorn 
HagaZiekenhuis, loc. Leyenburg M JW Götte M Hugo; E Karijodikoro; C de Jonge; H de Lange-van Bruggen 
Slingeland Ziekenhuis  JCM Hal van;  
DAAM 
Schellings 
  
Ziekenhuis Gelderse Vallei F den Hartog  D van Wijk; M Singerling  
Martini Ziekenhuis GL Bartels M Hendriks - van Woerden; B van der Roest; Z Aukema-Wouda 
Kennemer Gasthuis - locatie EG JF Küpper J Vooges; C Kalkman  
Röpcke Zweers Ziekenhuis HP Beijerbacht  M Beijering; B Baarslag 
Atrium Medisch Centrum T Lenderink I Kremer 
Spaarne Ziekenhuis   AFM Kuijper M Schiks; E Bayraktar 
Orbis Medisch Centrum MERM van 
Daele 
O Douven; M Bouwens 
Gelre Ziekenhuizen, loc. Zupthen NYY Al-Windy T Tiemes; M van Nistelrooy 
Ziekenhuis Bethesda SHK The F Geerlings; J Krikken 
Norway 
NPI: F Kontny 
Stavanger Universitetssjukehus Helse Stavanger D Nilsen S Moen; T Brugger-Andersen; V Ponitz 
Diakonhjemmet Sykehus EH Oie  H Muriq; RU Quazi  
Sykehuset Ostfold RAM deBoer    
Portugal 
NPI: C Gavina 
Unidade Local de Saúde de Matosinhos C Gavina C Ponte; M Centeno; H Maia; I Goncalves; R Barrades; J Tavares 
Unidade Saúde Familiar Santo André de Canidelo F Ferreira L Alves 
Unidade Saúde Familiar São João P Santos C Franclim 
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Hospital de Santiago JF Santos   
Hospital da Cruz Vermelha F Matias   
Hospital da Luz D Ferreira MB Fonseca 
Hospital de Faro J Mimoso W Santos; J Amando 
Unidade Local de Saúde do Alto Minho  R Lima R Lima; CC Dias; C Mateus; V Enes; G Silva 
Hospital de Braga A Gaspar  J Oliveira; M Goncalves 
Romania 
NPI: S Balanescu 
Spital Judetean de Urgenta  G Stanciulescu    
Spital Clinic Judetean Urgenta Arad D Darabantiu  AM Pop; CD Patrascanu 
Spital Clinic de Recuperare  D Zdrenghea  I Gusetu 
Spitalul Judetean Drobeta-Turnu Severin N Trocan  V Toman; J Cristian 
Spitalul Clinic de Urgenta Bucuresti  M Dorobantu  O Tautu; I Petre; A Deaconu 
Spital Clinic Municipal de Urgenta  M C Tomescu  I M Citu 
Spitalul Universitar de Urgenta Elias  S Huidu  L Ionescu 
Centru Clinic de Cardiologie  R Musetescu D Toader 
Spitalul Judetean de Urgenta 'Sf. Pantelimon' 
Focsani 
C Bengus  M Miron; M Burca; V Ochean 
Spital Judetean de Urgenta Braila M Bogdan L Serban 
Spitalul Monza Bucuresti  S Balanescu C L Caldararu; T Cristion-Razvan; A Linte; A Georgescu 
Spital Clinic de Urgenta Sf. Pantelimon  L Protopopescu    
Spitalul Clinic Judetean de Urgenta Sibiu I Manitiu  M Teodoru; C Zagoni 
Clinica Polisano M Vladoianu O Purcar; R Dobrin 
Institutul de Boli Cardiovasculare Timisoara L Petrescu  D Maximov; R Dan; R Nicola 
Spain 
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NPI: AF Ortiz 
Complejo Hospitalario Virgen del Rocio  JN Portero   
Hospital de Baza MM Robles; 
G Arquero 
  
Hospital General de Vic  JS Serrasolsas RR Fernandez 
Hospital Vall D´Hebron JAB Riu J Baneras 
Complejo Hospitalario Universitarion de Santiago PM Ramos J Seijas 
Hospital General Universitario de Alicante VIA Esteban RA Ferrer 
Hospital Clinico San Carlos AF Ortiz R Guerra; S Mera 
Hospital Puerta de Hierro P Pavia A Gonzalez; M Cordoba 
Hospital del Mar de Barcelona JB Cortada P Cabero; C Soleer 
Hospital de Bellvitge AC Filiat M Nato; O Alegre 
Hospital Virgen del Mar de America JLB Coronado   
Hospital San Pedro de Alcantara FJF Portales P Dominguez; S Romani 
Hospital Ramón y Cajal M Sanmartin LM Rincon; D del Van 
Hospital 12 de Octubre RM Asenjo   
Hospital Virgen de Arrixaca F Marin Ortuno E Orenes; M Quintana Giner 
Hospital de Lerida M Pique M Agusti; L Barta 
Hospital Principe de Asturias A Garcia Lledo  JAS Barrio; FL Bachiller; JG Pérez-Velasco; VP Mir; VB Jimenez; GB 
Lopez 
Hospital Son Llatzer T Ripoll Y Gomez 
Hospital Univeritario San Cecilio BG Extremera; 
JGS Ramos 
E Jimenez; E Garcia; ML Abaraca; A Guarnido; I Merida 
Turkey 
NPI: E Bozkurt 
T.C. Sağlık Bakanlığı Yıldırım Beyazıt Üniv. Atatürk E Bozkurt  H Ayhan  
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For Peer Review
Eğt. Arşt. Hastanesi 
Recep Tayyip Erdoğan Üniv. Tıp Fakültesi M Bostan Z Karadag; G Irfanoglu 
T.C. Sağlık Bakanlığı Yıldırım Beyazıt Üniv. 
Dışkapı Eğt. Arşt. Hastanesi 
E Yeter A Nallbani 
Mersin Üniversitesi Tıp fakültesi A Camsari İT Ozcan 
Diyarbakır Eğit. Araş. Hast R Altindag S Akkaya; İ Erkek 
İstanbul Üniversitesi Cerrahpaşa Tıp Fakültesi 
Yerleşkesi 
İ Keles OO Tok; M Cimci 
Hacettepe Üniversitesi Tıp Fakültesi E Atalar H Yorgun 
Adnan Menderes Üniversitesi Araşt Hastanesi C Ceyhan H Gungor 
UK 
NPI: K Ray 
Craigavon Area Hospital A Moriarty A Mackin; A Mcmullan 
Northern General Hospital R Storey C Bridge; S Spedding-Dutton; G Sangha; R Ecob 
Hairmyres Hospital B O'Rourke S Clements; C Malcolson 
Monklands Hospital A Pell J Anderson 
Musgrove Park Hospital, Taunton D McKenzie; 
M Dayer 
K James; F Venn; P Hill 
St George’s Hospital NHS Trust Research Centre R Sharma D Cole 
Papworth Hospital NHS Foundation Trust  S Hoole R McClean; S Meakins; T McGovern; A Shook; G Charman; S Smith 
Barnet General Hospital A Bakhai L Lim; S Hoole; S Metherell; Vi Krishnamurthy 
Royal Wolverhampton NHS Trust, New Cross 
Hospital 
J Cotton A Smallwood 
North America 
Canada 
NPI: S Goodman 
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Clinique Sante Cardio MC C Constance  M Gauthier; J Piche-Giroux 
Vizel Cardiac Research S Vizel  B Fox 
Glanz Medicine Professional Corporation A Glanz  C Vilag 
Hamilton Health Sciences - General Site A Lamy  P Power; T Rizzo; F Toito 
Brampton Research Associates M Gupta  CD La Cruz; R Kahlon; Y Thevakumaran 
St-Jerome Medical Research Inc. Y Pesant  V Sardin; S Grigorova; M Lambert; YS Laframboise 
York PCI Research W Cantor  K Robbins; N Popel 
Lawson Health Research Institute R Petrella  C Dihel; J Duncan; C Bartol; Z Majeed 
Saint John Medical Clinic R Bessoudo 
(Marr)  
G O'Blenis 
Cambridge Cardiac Care Inc. AS Pandey  M Pandey; S Juranics 
Keele Medical Place A Bell  P Kailey 
Yorkview Medical Center I Teitelbaum  J Teitelbaum; J Dimarino 
Viacar Recherche Clinique Inc.  R Chehayeb  P Carmichael 
Centre de Sante et de Services Sociaux de Thetford R Dupuis  F Ouimet; M Couture; B Roberge 
USA 
NPI: M Cohen 
Central Bucks Cardiology JJ Kmetzo D Taylor; R Riley  
Ventura Cardiology Consultants Medical Group N Mayer B Mitchell  
Atlanta Heart Specialists LLC N Singh K Turner 
Doylestown Cardiology Specialists-VIAA R Sangrigoli L Schwarz; S Martin 
Kootenai Heart Clinics LLC W Bennett L Passey; A Kavanaugh  
Fletcher Allen Health Care D Schneider M Rowen; K Begin 
Maine Research Associates R J Weiss D Murphy; A Gagergan 
Minneapolis Heart Institute Foundation M Newell M Buescher  
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Heart Center Research LLC N K Mann B Lamb  
The Miriam Hospital P Gordon L Felix; J A Gomes 
Heart and Vascular Center of West TN E Korban A Harrington 
Jackson Cardiology Associates PC R Mehta Kristy Watkins 
Baylor Research Institute M McKenzie R Buckner; IS Mohiuddin 
Cardiovascular Specialists of Central Maryland K Friedman T Burley  
Harbor - UCLA Medical Center WJ French CC Morales 
Duke TY Wang S Decker; R Mehta 
North Ohio Research Ltd W Sheldon A Bohn; K Humphrey; M Fazio 
Clearwater Cardiovascular and Interventional 
Consultants 
JK Amin M Cameron; L Selker 
Heart Care Center M Baig C Yough 
Virginia Heart T Haddad J Jain; D Overbeck  
Eastern Maine Medical Center A Wiseman A Coombs 
Northwest Heart Clinical Research, LLC A Soni S Bellini; D Golen 
Virginia Cardiovascular Associates H Taheri K Morgan  
South FL Research Group, LLC J Roberts K Shatsky 
UNC Heart and Vascular Center P Kaul A Que-Xu 
UPMC Heart and Vascular Institute - Shadyside K Tummalapalli M Travis; A Malecky 
South Miami Hospital J Ghitelman J Jean-Mary 
Cardiology Associates of New Jersey A Schwarcz   
Long Island Cardiovascular Consultants R D'Agostino L Lavelle 
CAPRI LLC R Davidson S Davidson 
Apex Research Institute J Duffy (Tonkon) J Dolen; M Gonzalez 
Robert Packer Hospital E Kaluski C Lanning (Lorraine Barten) 
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Swedish Medical Center J Petersen II   
St. Vincent Medical Group JS Rossi J Gall 
Southern Medical Group, P.A. W Batchelor P Knap 
South America 
Argentina 
NPI: JLCN Estrada 
Hospital Italiano de Buenos Aires JLCN Estrada  E Castillo 
Fundación Favaloro para la Investigación y la 
Docencia Médica 
EA Duronto L Arrechavala 
Hospital Central de Mendoza RBS Zarandon O Caruso; G Segui 
Sanatorio El Carmen EA Falu MC Iriarte 
ICBA - Instituto Cardiovascular de Buenos Aires MS Trivi A Navarro 
Instituto de Cardiología Juana Francisca Cabral SM Macin MJG Salazán; L C Vargas 
Sanatorio Profesor Itoiz CA Rapallo V Ferreiro; R Santos 
Sanatorio Modelo de Quilmes S.A. AD Hrabar CM Funosas; A Cappi 
Hospital Universitario Austral HE Fernandez G Marinsalta; J-M Bonorino 
Sanatorio Los Arcos SM Rahabani   
Sanatorio Mayo Privado S.A.  DJ Anauch M Barrionuevo 
Hospital Español DL Paolantonio A R Quiroga; I Gribaudo; G Matkovich 
Hospital Privado Centro Médico de Córdoba S.A. OA Salomone N Konicoff 
Brazil 
NPI: JC Nicolau 
Hospital Santa Isabel  APM Kormann A Marchi; J Spricigo 
Hospital Universitário UFMS  DG da Silva Jr RM Uehara; R Nakasone 
Instituto do Coração de Marília  JC Ferreira L Silva; D Funai; D Rodrigues 
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Braga 
Hospital de Base - FAMERP  LN Maia RP de Brito; O da Silva Jr; N Goes 
Colombia 
NPI: N Jaramillo 
Centro de Investigaciones Clínicas S.A.S.  C Arana  M Ceballos; M Gonzalez; O Sierra 
IPS Unidad Cardiologica de Cartagena. M Herrera  D Perez; M Jazime 
Asociación IPS Medicos Internistas de Caldas  DI Molina  H Urrea; JM Patiño; GC Giraldo; I Rodriguez 
Centro de Investigaciones Cardiodiagnostico S.A. / 
Fundación del Caribe para la Investigación 
Biomedica (Fundacion BIOS) 
M Urina  N Ramirez 
Centro de medicina del Ejercicio y Rehabilitacion 
Cardiaca 
N Jaramillo  M Toloza; G Rasterepo; RMT Giraldo; V Jaramillo 
Clinica Cardiovascular Santa Maria  R Fernandez  E Gonzalez; A Quintero 
Instituto del Corazon de Bucaramanga  B Vesga  PS Delgado; DPS Avciniegas; H Hernandez; L Rodriguez 
Cardiología Hugo Duque, Centro de Excelencia 
S.A.S. CHD Cardiology 
H Duque  M Zuluaga 
IPS Centro Cientifico Asistencial Jose Luis Accini 
SAS 
JL Accini  T Valencia 
Centro de diagnostico Cardiológico F Manzur  D Rosales; D Boneu; F Manzur 
Centro de Investigacion Clinica Avanzada y 
Multidisciplinaria, CICLAM S.A.S. 
C Jaramillo G PG Lopez; ML Jaramillo; C F. Jaramillo; L Velasquez 
Mexico 
NPI: FP Padilla 
Unidad Medica de Alta Especialidad; Hospital de 
Cardiología. Centro Médico Nacional Siglo XXI, 
Instituto Mexicano del Seguro Social 
ED y Díaz   
 Sitio Dr. Alberto Esteban Bazzoni Ruiz AB Ruiz D Monreal; AC Tovar 
Cardiosalud GR Martínez V Delgado; C Preciado; PS Guzman 
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Cardioarritmias e Investigacion SC IR Briones M Ramos 
Consultorio Privado Dr. Padilla FP Padilla S Fernandez; VM Delgado; L Ruiz 
Hospital General de Puebla “Dr. Eduardo Vázquez 
Navarro”  
JCP Alva  M Macip; SR Paboios 
Unidad de Investigacion en Salud O Fierro Fierro I Gonzalez; DAS Carreon 
Venezuela 
NPI: ML Fariña 
Hospital Universitario de Caracas N Antepara A Ruggiero; S Martinez 
Hospital Militar "Dr. Carlos Arvelo" S Tovar E Moya; L Ramirez; M Wilman 
Hospital Universitario "Dr. Angel Larralde" ML Fariña   
Centro Policlínico La Viña C Delgado R Rey  
Unidad Cardiológica Clínica IDET. Caracas Á Avendaño  A Sanchez; J Marin 
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APPENDIX II: Study variables and healthcare resource utilization 
Variable Details 
Baseline / Enrollment  
Clinic/outpatient center type University General Hospital (UGH), n = 49; non-UGH, n = 144; Other 
type of hospital/clinic (CCU/cardiology/cardiovascular/research), n = 
137; Private clinic, n = 24; Ambulance, n = 10 
Patient characteristics Gender, age, race (latter if allowed by local regulations) 
Place of residence  Rural, metropolitan 
Educational level Measured by years of education due to differences in degree 
programs across countries  
Professional status Employed, self-employed, unemployed, homemaker, retired, student, 
sick leave, maternity leave, disability pension 
Type of residence  Home, nursing home, etc. 
Living arrangement status  Living alone, not living alone 
Income  Only in countries where feasible 
Health insurance status  Only in countries where feasible 
Cardiovascular risk factors Hypertension, hyperlipidemia, diabetes mellitus, obesity, smoking, 
family history of CAD 
Major bleeding risk factors History of major bleeding or severe liver disease 
History of other CVD PAD, HF, stroke, TIA, ICD, permanent pacemaker, VTE, valve 
repair/replacement, AF 
Medical history re index MI 1 
to 3 y prior 
Date of occurrence and management strategy (PCI, CABG or 
medical) 
Antithrombotic medication 
use  
Antiplatelets (incl OTC aspirin), and anticoagulants since last MI; 
dose, duration, switching, planned/unplanned treatment interruptions 
and reasons eg, intolerance, hypersensitivity, GI bleeding, other 
bleeding complications, other GI side effects  
Medical conditions that may 
impact antithrombotic therapy 
use or study outcomes  
History of peptic ulcer, renal-, liver-, disease, and lung-disease, other 
indices precluding frailty, previous invasive surgical treatment 
considered relevant by the investigator 
Medication use at enrollment 
 
Oral antiplatelets, anticoagulants, antidiabetic drugs, lipid-lowering 
agents, ACE inhibitors, ARBs, diuretics and β-blockers, and 
antidepressants 
Healthcare resource use 
related to cardiovascular or 
bleeding conditions during the 
6 months preceding 
enrollment 
Medication use, and resource use related to medical 
visits/procedures/investigations: GP or specialist visit, ER admission, 
number of event-related hospitalizations and duration of stay, and 
procedures and interventions performed 
Routine physical examination  Heart rate, seated blood pressure, weight, height, waist 
circumference (if current normal practice) 
Laboratory safety measures Serum creatinine (renal function), lipid profile (total cholesterol, HDL, 
LDL, triglyceride), hemoglobin and glucose/HbA1c; if available and 
performed within 3 months prior to the visit or 1 month after 
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enrollment 
Quality of life evaluation EuroQol 5-Dimensions (EQ-5D-3L) 
Follow-up  
Clinical events – Primary 
variable 
MI, unstable angina with urgent revascularization, stroke or death 
(any cause) - Primary 
Bleeding events requiring 
medical attention 
TIMI definition: needing intervention (practitioner-guided 
medical/surgical treatment, including temporary or permanent 
discontinuation/change in medication/study drug dose), or leading to 
hospitalization, or prompting evaluation (unscheduled visit to a HCP) 
and diagnostic testing (laboratory or imaging) 
Other events of interest Including pneumonia and associated death outcome, and macular 
degeneration 
Intercurrent medical 
procedures and 
hospitalizations unrelated to 
predefined events 
If hospitalization occurred, patients were asked to confirm the 
duration and primary cause 
Prescription status of 
antithrombotic medication  
 
Antiplatelets (including OTC aspirin) and anticoagulants, dose, 
duration, adherence, planned/unplanned treatment interruptions, and 
reasons for interruptions, eg, intolerance, hypersensitivity, GI 
bleeding, other bleeding complications, other GI side effects 
Other medications  Antidiabetic drugs, lipid-lowering agents, ACE inhibitors, ARBs, 
diuretics, β-blockers, and antidepressants 
Quality of life evaluation EuroQol 5-Dimensions (EQ-5D) 
Healthcare resource use 
related to cardiovascular or 
bleeding conditions needing 
medical attention within 6 
months since the last call/visit 
Patient: 
Medication use 
Resource use related to medical visits/procedures/investigations: GP 
or specialist visit, ER admission 
Productivity loss: employment status for patient and the primary 
informal caregiver (latter who stays at home from employment to 
assist the patient); number of event-related days’ sick leave for the 
patient and/or informal caregiver if either employed/self-employed 
Intercurrent medical procedures/hospitalizations: number of 
hospitalizations, primary cause of and duration of stay, not related to 
a predefined event 
Event treating physician/hospital: 
Hospitalization: primary cause, number, and duration of stay where 
event related including level of care per hospitalization (eg, how many 
days in ICU, general ward, etc.) 
Procedures/interventions 
Investigations 
Where applicable, in-hospital resource utilization before patient death  
ACE, angiotensin-converting enzyme; AF, atrial fibrillation; ARB, angiotensin receptor blocker; CABG, coronary 
artery bypass graft; CAD, coronary artery disease; CVD, cardiovascular disease; ER, emergency room; GI, 
gastrointestinal; GP, general practitioner; HbA1c, glycated hemoglobin; HCP, healthcare professional; HDL, high-
density lipoprotein; LDL, low-density lipoprotein; HF, heart failure; ICD, implantable cardioverter defibrillator; ICU, 
intensive care unit; MI, myocardial infarction; OTC, over the counter; PAD, peripheral artery disease; PCI, 
percutaneous coronary intervention; TIA, transient ischemic attack; TIMI, 'Thrombolysis In Myocardial Infarction'; 
VTE, venous thromboembolism 
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